atamparib

Atamparib (formerly RBN-2397) is a first-in-class, orally bioavailable small molecule inhibitor that selectively targets poly-ADP ribose polymerase 7 (PARP7). PARP7 is a mono-ADP-ribosyltransferase that is often overexpressed in various cancers, where it acts to suppress the type I interferon response, thereby allowing tumors to evade the immune system. By inhibiting PARP7, atamparib promotes the induction of interferon-stimulated genes and enhances anti-tumor immunity. Originally developed by Ribon Therapeutics and later acquired by Nerviano Medical Sciences in November 2024, the drug is currently in Phase Ib/II clinical development for the treatment of advanced solid tumors, including non-small cell lung cancer (NSCLC) adenocarcinoma. Early clinical data has demonstrated high selectivity and a favorable safety profile in over 200 treated patients.

Other names

atamparib